{"transactions":[{"id":4614947,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-10T21:08:03.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":275000,"derivative":{"exercise_price":37.37,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001193125-26-388033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526388033/ownership.xml","form_type":"4"}},{"id":940736,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T19:08:04.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002980","document":"tm262917-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000110465926002980/tm262917-6_4seq1.xml","form_type":"4"}},{"id":1119145,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T17:14:19.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000091228225000615/form4.xml","form_type":"4"}},{"id":1301306,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-16T08:04:21.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 15, 2025, the Reporting Person was granted an option to purchase 44,000 shares of common stock, which vests in three equal installments on the first three anniversaries of the grant date, subject to his continued service as a Director through the vesting period."}],"balance_after":44000,"derivative":{"exercise_price":0.3465,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-25-003952","document":"tm252892-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000110465925003952/tm252892-2_4seq1.xml","form_type":"4"}},{"id":1486121,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-07T20:55:27.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":13500,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001415889-24-016087","document":"form4-06082024_120623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000141588924016087/form4-06082024_120623.xml","form_type":"4"}},{"id":1640545,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-15T18:14:09.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of February 15, 2024, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date."}],"balance_after":54000,"derivative":{"exercise_price":1.3,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001415889-24-003984","document":"form4-02152024_110201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000141588924003984/form4-02152024_110201.xml","form_type":"4"}},{"id":1773132,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief R&D Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:25.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":99.12,"expiration_date":"2033-06-12","underlying":"Class A common stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-23-019537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019537/doc4.xml","form_type":"4"}},{"id":1773131,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief R&D Officer"}}],"security":"Class A common stock","published_at":"2023-09-26T16:30:25.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares represent RSUs, which were to vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019537/doc4.xml","form_type":"4"}},{"id":1855595,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief R&D Officer"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-06-14T16:26:37.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, representing a right to purchase a total of 90,000 Class A shares, become exercisable as to 22,500 on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":99.12,"expiration_date":"2033-06-12","underlying":"Class A common stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-23-037021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037021/doc4.xml","form_type":"4"}},{"id":1855594,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief R&D Officer"}}],"security":"Class A common stock","published_at":"2023-06-14T16:26:37.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001209191-23-037021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037021/doc4.xml","form_type":"4"}},{"id":3091370,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CMO"}}],"security":"Restricted Stock Units","published_at":"2020-07-02T16:37:15.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-040356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040356/doc4.xml","form_type":"4"}},{"id":3091369,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:37:15.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":125000,"price":7.89,"value":986250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":10.11,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-20-040356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040356/doc4.xml","form_type":"4"}},{"id":3231578,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-03T19:02:03.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options vest as follows: 25% of the shares will vest one year from the Vesting Commencement Date of February 3, 2020, and the remaining shares will vest ratably over the next 36 months."}],"balance_after":125000,"derivative":{"exercise_price":10.11,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-20-015668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120015668/doc4.xml","form_type":"4"}},{"id":3231577,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CMO"}}],"security":"Common Stock","published_at":"2020-03-03T19:02:03.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restrict Stock Units (\"RSUs\") in consideration of services to be rendered. 1/3 of the RSUs vest on each of March 1, 2021; March 1, 2022; and March 1, 2023, subject to the Reporting Person's Continuous Service under the Issuer's plan documents as of each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Grant of Restrict Stock Units (\"RSUs\") in consideration of services to be rendered. 1/3 of the RSUs vest on each of March 1, 2021; March 1, 2022; and March 1, 2023, subject to the Reporting Person's Continuous Service under the Issuer's plan documents as of each such date."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-20-015668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120015668/doc4.xml","form_type":"4"}},{"id":3558299,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-10T16:26:26.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":60000,"derivative":{"exercise_price":6.81,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-024240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119024240/doc4.xml","form_type":"4"}},{"id":3558298,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-04-10T16:26:26.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":49141,"source":{"system":"sec-edgar","filing":"0001209191-19-024240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119024240/doc4.xml","form_type":"4"}},{"id":3582739,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-03-21T16:45:23.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":2374,"price":8,"value":18992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $7.95 to $8.04.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":19141,"source":{"system":"sec-edgar","filing":"0001209191-19-020785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119020785/doc4.xml","form_type":"4"}},{"id":3984817,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-22T17:51:15.000Z","date":"2018-03-21","kind":"sale","acquired":false,"shares":1252,"price":25.94,"value":32476.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $25.78 to $25.94.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":21515,"source":{"system":"sec-edgar","filing":"0001209191-18-021307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118021307/doc4.xml","form_type":"4"}},{"id":4002861,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-09T20:50:24.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":54750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":54750,"derivative":{"exercise_price":25.66,"expiration_date":"2028-03-05","underlying":"Common Stock","underlying_shares":54750},"source":{"system":"sec-edgar","filing":"0001209191-18-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118018673/doc4.xml","form_type":"4"}},{"id":4002860,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-09T20:50:24.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":9125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":22767,"source":{"system":"sec-edgar","filing":"0001209191-18-018673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118018673/doc4.xml","form_type":"4"}},{"id":4374484,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-03-22T17:05:12.000Z","date":"2017-03-21","kind":"sale","acquired":false,"shares":733,"price":17.04,"value":12490.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $16.99 to 17.12.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":13642,"source":{"system":"sec-edgar","filing":"0001209191-17-022340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919117022340/doc4.xml","form_type":"4"}},{"id":4485074,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-20T18:14:19.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall become vested according to the following schedule: 1/48th of the shares subject to the option shall vest monthly beginning on February 1, 2017 for 48 months."}],"balance_after":41250,"derivative":{"exercise_price":16.61,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0001209191-17-004977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919117004977/doc4.xml","form_type":"4"}},{"id":4485073,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-20T18:14:19.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest 1/4th on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021."}],"balance_after":14375,"source":{"system":"sec-edgar","filing":"0001209191-17-004977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919117004977/doc4.xml","form_type":"4"}}]}